`
`PR Tufts CSDD 2014 Cost Study | Tufts Center for the Study of Drug Development
`
`Tufts Center for the Study of Drug Development
`Tufts University
`
`Links | Directions | Contact Us
`
`Home News ∕ Complete Story ∕ PR Tufts CSDD 2014 Cost Study
`
`News
`
`November 18, 2014
`Cost to Develop and Win Marketing Approval for a New Drug Is $2.6
`Billion
`
`BOSTON – Nov. 18, 2014 – Developing a new prescription medicine that gains marketing approval, a process
`often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts
`Center for the Study of Drug Development.
`
`The $2,558 million figure per approved compound is based on estimated:
`
`Average outofpocket cost of $1,395 million
`Time costs (expected returns that investors forego while a drug is in development) of $1,163 million
`
`Estimated average cost of postapproval R&D—studies to test new indications, new formulations, new dosage
`strengths and regimens, and to monitor safety and longterm side effects in patients required by the U.S. Food
`and Drug Administration as a condition of approval—of $312 million boosts the full product lifecycle cost per
`approved drug to $2,870 million. All figures are expressed in 2013 dollars.
`
`The new analysis, which updates similar Tufts CSDD analyses, was developed from information provided by 10
`pharmaceutical companies on 106 randomly selected drugs that were first tested in human subjects anywhere in
`the world from 1995 to 2007.
`
`“Drug development remains a costly undertaking despite ongoing efforts across the full spectrum of
`pharmaceutical and biotech companies to rein in growing R&D costs,” said Joseph A. DiMasi, director of
`economic analysis at Tufts CSDD and principal investigator for the study.
`
`He added, “Because the R&D process is marked by substantial technical risks, with expenditures incurred for
`many development projects that fail to result in a marketed product, our estimate links the costs of unsuccessful
`projects to those that are successful in obtaining marketing approval from regulatory authorities.”
`
`In a study published in 2003, Tufts CSDD estimated the cost per approved new drug to be $802 million (in 2000
`dollars) for drugs first tested in human subjects from 1983 to 1994, based on average outofpocket costs of
`$403 million and capital costs of $401 million.
`
`The $802 million, equal to $1,044 million in 2013 dollars, indicates that the cost to develop and win marketing
`approval for a new drug has increased by 145% between the two study periods, or at a compound annual growth
`rate of 8.5%.
`
`http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study
`
`1/3
`
`MYLAN - EXHIBIT 1073
`Mylan Laboratories Limited v. Aventis Pharma S.A.
`IPR2016-00712
`
`
`
`PR Tufts CSDD 2014 Cost Study | Tufts Center for the Study of Drug Development
`2/1/2017
`According to DiMasi, rising drug development costs have been driven mainly by increases in outofpocket
`costs for individual drugs and higher failure rates for drugs tested in human subjects.
`
`Factors that likely have boosted outofpocket clinical costs include increased clinical trial complexity, larger
`clinical trial sizes, higher cost of inputs from the medical sector used for development, greater focus on targeting
`chronic and degenerative diseases, changes in protocol design to include efforts to gather health technology
`assessment information, and testing on comparator drugs to accommodate payer demands for comparative
`effectiveness data.
`
`Lengthening development and approval times were not responsible for driving up development costs, according
`to DiMasi.
`
`“In fact,” DiMasi said, “changes in the overall time profile for development and regulatory approval phases had
`a modest moderating effect on the increase in R&D costs. As a result, the time cost share of total cost declined
`from approximately 50% in previous studies to 45% for this study.”
`
`The study was authored by DiMasi, Henry G. Grabowski of the Duke University Department of Economics, and
`Ronald W. Hansen at the Simon Business School at the University of Rochester.
`
`ABOUT THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT
`
`The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides
`strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency
`of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of
`indepth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes
`Tufts CSDD Impact Reports, a bimonthly newsletter providing analysis and insight into critical drug
`development issues.
`
`end
`
`Contacts: Tufts Center for the Study of Drug Development
`
` Sandra Peters – 6176362185
`
` Sandra.Peters@tufts.edu
`
`
`
` Business Communication Strategies
`
` Peter Lowy – 6177349980
`
` lowy@buscom.com
`
`
`
`For the backgrounder and slides for the Tufts CSDD Cost Study, click here.
`
`News
`Quarterly Updates
`Press Releases
`Staff Presentations
`
`ABOUT RESEARCH COURSES & FORUMS LIBRARY & BIBLIOGRAPHY REPORTS SPONSORED
`RESEARCH NEWS
`
`http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study
`
`2/3
`
`
`
`2/1/2017
`
`Tufts Center for the
`Study of Drug Development
`
`PR Tufts CSDD 2014 Cost Study | Tufts Center for the Study of Drug Development
`Tufts University
`Phone: 6176362170
`Copyright ©2017
`75 Kneeland Street
`Fax: 6176362425
`Tufts Center for the
`Suite 1100
`Email: csdd@tufts.edu
`Study of Drug Development
`Boston, MA 02111
`USA
`
`Privacy Policy
`
`All Rights Reserved
`
`http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study
`
`3/3
`
`